Did you miss the live broadcast? Stay engaged in recent updates and key findings in lung cancer immuno-oncology with this webcast from our virtual grand rounds series.
1.25 AMA PRA Category 1 Credit(s)™
Apr 18, 2019
Apr 18, 2020
Next Steps in Lung Cancer Immunotherapy
Solange Peters, MD, PhD
Solange Peters, MD, PhDUniversity of Lausanne
This educational activity is designed to meet the needs of medical oncologists and other healthcare professionals involved in the treatment of patients with breast cancer, bladder cancer, head and neck cancer, lung cancer, and melanoma.
After successful completion of this educational activity, participants should be able to:
- Discuss the rationale for using immune checkpoint inhibitors, alone and in combination with other novel agents, for the treatment of solid tumors
- Formulate optimal treatment plans that use immune checkpoint inhibitors for the treatment of solid tumors
- Analyze clinical trial data evaluating the efficacy and safety of immune checkpoint inhibitors for the management of solid tumors
- Develop treatment plans to manage immune-related adverse events associated with immune checkpoint inhibitors
This educational activity is supported by a grant from Merck Sharp and Dohme Corp.
In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and prIME Oncology. Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
The Postgraduate Institute for Medicine designates this enduring material for a maximum of 1.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
This activity is jointly provided by Postgraduate Institute for Medicine and prIME Oncology.
Method of Participation
Estimated time to complete activity: 1.25 hours
To contact Postgraduate Institute for Medicine please visit www.pimed.com.
Disclosure of Relevant Financial Relationships
Postgraduate Institute for Medicine (PIM) and prIME Oncology require instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to PIM policy. PIM is committed to providing its learners with high quality activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.
The faculty reported the following financial relationships or relationships to products or devices they or their spouses/life partners have with commercial interest related to the content of this activity:
Dr Peters has disclosed advisory board participation and receipt of honorarium from Daiichi Sankyo, Debiopharm, Eli Lilly, F. Hoffman-La Roche, Foundation Medicine, Illumina, Janssen, Merck Sharpe and Dohme, Merck Serono, Merrimack, Novartis, PharmaMar, Pfizer, Regeneron, Sanofi, Seattle Genetics, and Takeda.Dr Peters also disclosed participation in a talk and receipt of honorarium from AstraZeneca, Boehringer-Ingelheim, Bristol-Myers Squibb, Eli Lilly, F. Hoffman-La Roche, Merck Sharpe and Dohme, Novartis, Pfizer, and Takeda. She further disclosed support to her institution for investigation in trials from Amgen, AstraZeneca, Boehringer-Ingelheim, Bristol-Myers Squibb, and Clovis. She has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in her presentation.
Postgraduate Institute for Medicine Planners and Managers have disclosed no relevant financial relationships.
The employees of prIME Oncology have disclosed:
- Briana Betz, PhD (scientific content manager) – worked on non–CME certified projects in the last 12 months supported by Helsinn Healthcare, ImmunoGen, Karyopharm Therapeutics, Novartis, Pfizer, and TG Therapeutics
- Heather Tomlinson, ELS (editorial content reviewer) – worked on non–CME certified projects in the last 12 months supported by AstraZeneca, Clovis Oncology; F. Hoffmann-La Roche Ltd; ImmunoGen; Merck KGaA, Darmstadt, Germany; Pfizer; Novartis Oncology; Puma Biotechnology; and Tesaro
Disclosure Regarding Unlabeled Use
This activity may contain discussion of published and/or investigational uses of agents that are not indicated by the US Food and Drug Administration or European Medicines Agency. Please refer to the official prescribing information for each product discussed for discussions of approved indications, contraindications, and warnings.
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients’ conditions and possible contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.